Preoperative Intravitreal Ranibizumab for Persistent Diabetic Vitreous Haemorrhage: A Randomized, Double-masked, Controlled Study.

Trial Profile

Preoperative Intravitreal Ranibizumab for Persistent Diabetic Vitreous Haemorrhage: A Randomized, Double-masked, Controlled Study.

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 06 Jan 2017

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Vitreous haemorrhage
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Oct 2014 Accrual to date is 104% according to United Kingdom Clinical Research Network record
    • 15 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.
    • 04 Aug 2014 Accrual to date is 91% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top